Equities research analysts predict that Omeros Co. (NASDAQ:OMER) will report earnings of ($0.12) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Omeros’ earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.22). Omeros posted earnings per share of ($0.53) during the same quarter last year, which suggests a positive year-over-year growth rate of 77.4%. The company is scheduled to announce its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Omeros will report full year earnings of ($0.31) per share for the current year, with EPS estimates ranging from ($0.78) to $0.17. For the next financial year, analysts anticipate that the business will post earnings of $0.81 per share, with EPS estimates ranging from ($0.96) to $2.57. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Omeros.

Omeros (NASDAQ:OMER) last posted its earnings results on Friday, March 1st. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.27. The business had revenue of $22.02 million for the quarter, compared to analyst estimates of $22.42 million. Omeros’s revenue was up 60.0% compared to the same quarter last year. During the same period last year, the business earned ($0.34) EPS.

OMER has been the subject of several recent analyst reports. HC Wainwright set a $34.00 target price on Omeros and gave the stock a “buy” rating in a research note on Thursday, December 13th. Zacks Investment Research raised Omeros from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Thursday, March 7th. Finally, ValuEngine raised Omeros from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $27.00.

OMER stock opened at $17.92 on Thursday. The firm has a market cap of $878.26 million, a price-to-earnings ratio of -8.07 and a beta of 3.60. Omeros has a 52-week low of $10.30 and a 52-week high of $27.00.

Several hedge funds and other institutional investors have recently modified their holdings of OMER. Millennium Management LLC grew its stake in shares of Omeros by 844.8% in the fourth quarter. Millennium Management LLC now owns 1,112,584 shares of the biopharmaceutical company’s stock valued at $12,394,000 after buying an additional 994,829 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of Omeros by 49.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock valued at $21,303,000 after buying an additional 632,840 shares in the last quarter. SG Americas Securities LLC purchased a new position in Omeros in the fourth quarter valued at $955,000. First Trust Advisors LP purchased a new position in Omeros in the fourth quarter valued at $879,000. Finally, Tibra Equities Europe Ltd purchased a new position in Omeros in the first quarter valued at $771,000. 49.19% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: What is a good rate of return for a mutual fund?

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.